Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomaras

Showing results (271-280 of 525) with videos related to

Pageof 53
Sort By:
The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 19, 2007
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120Farley Cleghorn, Jean W Pape, Mauro Schechter, et al.
Frontiers in Immunology|January 10, 2022
Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus ControllersTinashe E Nyanhete, Robert J Edwards, Celia C LaBranche, et al.
Mucosal Immunology|January 28, 2016
Distinct genital tract HIV-specific antibody profiles associated with tenofovir gelD Archary, K E Seaton, J S Passmore, et al.
Journal of Virology|February 4, 2012
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine designMattia Bonsignori, David C Montefiori, Xueling Wu, et al.
The Journal of Experimental Medicine|November 12, 2020
Vi-specific serological correlates of protection for typhoid feverCelina Jin, Jennifer Hill, Bronwyn M Gunn, et al.
Vaccine|January 11, 2011
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsMichael C Keefer, Sharon E Frey, Marnie Elizaga, et al.
Journal of Virology|March 5, 2010
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccinationStephanie A Freel, Laurie Lamoreaux, Pratip K Chattopadhyay, et al.
Nature Communications|July 3, 2019
Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformationsQifeng Han, Julia A Jones, Nathan I Nicely, et al.
JCI Insight|August 1, 2024
Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119Spyros A Kalams, Barbara K Felber, James I Mullins, et al.
Pageof 53

Showing results (271-280 of 525) with videos related to

Sort By:
Pageof 53
The Journal of Clinical Investigation|October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialPierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 19, 2007
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120Farley Cleghorn, Jean W Pape, Mauro Schechter, et al.
Frontiers in Immunology|January 10, 2022
Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus ControllersTinashe E Nyanhete, Robert J Edwards, Celia C LaBranche, et al.
Mucosal Immunology|January 28, 2016
Distinct genital tract HIV-specific antibody profiles associated with tenofovir gelD Archary, K E Seaton, J S Passmore, et al.
Journal of Virology|February 4, 2012
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine designMattia Bonsignori, David C Montefiori, Xueling Wu, et al.
The Journal of Experimental Medicine|November 12, 2020
Vi-specific serological correlates of protection for typhoid feverCelina Jin, Jennifer Hill, Bronwyn M Gunn, et al.
Vaccine|January 11, 2011
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsMichael C Keefer, Sharon E Frey, Marnie Elizaga, et al.
Journal of Virology|March 5, 2010
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccinationStephanie A Freel, Laurie Lamoreaux, Pratip K Chattopadhyay, et al.
Nature Communications|July 3, 2019
Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformationsQifeng Han, Julia A Jones, Nathan I Nicely, et al.
JCI Insight|August 1, 2024
Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119Spyros A Kalams, Barbara K Felber, James I Mullins, et al.
Pageof 53